SecBot SecBot
8-K ·Filed Nov 5, 2026

VXRT

Vaxart, Inc.
BEARISH
Impact 5/10
Horizonmonths Processed11d 10h ago SEC0001437749-26-035275
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The revenue collapse and widening loss reflect the lumpy nature of BARDA contract revenue recognition. The key catalyst is the Phase 2b COVID-19 data readout now pushed to mid-2027, extending the binary event timeline. Monitor cash burn rate and any new BARDA funding or partnership announcements that could extend the runway beyond Q2 2027.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$0.3700
T+0 close · Nov 5, 2026 · via day close
Latest settled
+2.43%
T+5 · $0.3790 · next T+20 in 20d
Vs SPY
−0.16%
α at T+5
Latest observation
−3.48%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $0.3700entry
  2. T+1 · 8d ago +1.97%α −0.39% · $0.3773
  3. T+5 · 4d ago +2.43%α −0.16% · $0.3790
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxart reported Q3 2026 revenue of $10.6M, down 85% from $72.4M a year ago, and a net loss of $17.7M versus an $8.1M loss in Q3 2025. The topline Phase 2b COVID-19 data readout from the full study is now expected by mid-year 2027, pushed back from the prior timeline of early 2027. Cash runway extends into Q2 2027.

Key Financial Metrics

EPS
−$0.07
est −$0.31 · +77.4%
Revenue
$10.6M
est $27.2M · -61.0% · -85.3% YoY
Rating
in line

Key Facts

  • Q3 2026 revenue $10.6M vs $72.4M in Q3 2025, an 85% decline
  • Net loss $17.7M in Q3 2026 vs net loss $8.1M in Q3 2025
  • EPS $(0.07) vs $(0.04) a year ago
  • Phase 2b COVID-19 topline data from full study (sentinel + main cohort) expected by mid-year 2027, delayed from early 2027
  • Cash, cash equivalents and short-term investments $65.5M as of Sep 30, 2026; runway into Q2 2027
  • Cumulative BARDA payments received $278.0M as of Sep 30, 2026
  • R&D expenses fell to $22.8M from $75.9M, reflecting lower clinical trial activity
  • Appointed Dr. Raquel Bono to Board of Directors

Financial Impact

Revenue declined 85% YoY to $10.6M; net loss widened to $17.7M from $8.1M; cash burn continues with $65.5M in liquid assets

revenuenet incomeepscash runway

Risk Factors

  • Phase 2b COVID-19 trial data delayed to mid-2027, extending period of binary risk
  • Revenue highly dependent on BARDA contract timing; Q3 2025 had $72.4M in revenue vs $10.6M in Q3 2026
  • Cash runway only into Q2 2027 with no approved products; may require additional financing
  • Pre-revenue clinical-stage biotech with no approved commercial products

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-035275
Document: vxrt20261105_8k.htm0001437749-26-035275
Document: 0001437749-26-035275-index-headers.html0001437749-26-035275
Document: 0001437749-26-035275-index.html0001437749-26-035275
Document: 0001437749-26-035275.txt0001437749-26-035275
8-K Data (Synthetic)0001437749-26-035275

Track record

23 reports on VXRT

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Viewing Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
  2. Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
  3. Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
  4. Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
  5. Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
  6. Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
  7. Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
  8. Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  9. Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  10. Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026